Differentiation Through Digital  

Digital technology is becoming increasingly important in the healthcare space. This was clearly reflected by the growing number of companies and events focused on the digital healthcare sector during JP Morgan/Biotech Week in San Francisco and new conferences dedicated to… Read »

Multiple Myeloma: The View from ASH 2018

Multiple myeloma (MM) is a deadly bone marrow cancer. In recent years, the treatment landscape for this disease has improved considerably. However, most patients still relapse and the need for new and better therapeutic options endures.   Encouraging news about… Read »

Happy New Year — Some Thoughts on the Year to Come

Welcome to 2019. We hope you enjoyed the holidays and look forward to meeting and greeting many of you next week in San Francisco for Biotech Week. Several members of the Bionest team will be in attendance, and if you’d… Read »

New Approaches to an Earlier Alzheimer’s Disease Diagnosis

We have written previously about the need for earlier diagnosis for Alzheimer’s disease (AD) and other dementias, a capability that could both aid in the discovery and the development of new therapies, and increase the chances for better patient outcomes… Read »

Neuromuscular Drug Development Summit

At the end of October, we attended the inaugural Neuromuscular Drug Development Summit. This new meeting brought together thought leaders from industry, academia, and the patient advocacy community to discuss scientific progress and issues affecting companies developing drugs for these… Read »

No Signs of Slowdown in NGS Sequencing Market

A couple of recent announcements in the next-generation sequencing (NGS) market got our attention as strong signs that both technology and applications are rapidly diversifying within that arena. It’s continued evidence that the NGS market is not only expanding rapidly,… Read »

Report on ESMO 2018 – Part Two

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings. Read our earlier report on combination therapy trials in melanoma,… Read »

Report on ESMO 2018 – Part One

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings, plus plenty of positive data from a variety of combination therapy… Read »

Artificial Intelligence and Real-time Data Improving Hospital Performance, Reducing Costs

Air traffic control-like, multiple screen “command centers,” are proving to be very effective tools for a small handful of busy hospitals to improve workflow efficiency, reduce wait times, allocate resources, and better orchestrate complex patient care and treatment.  The new… Read »

“All of Us” Achieves Substantial Recruitment Milestone in Record Time

In 2015, the U.S. National Institutes of Health (NIH) announced plans for a major precision medicine initiative. The program is designed to take into account individual differences in lifestyle, environment and biology by gathering health data over time from more than… Read »

1 2 3 14